TABLE 2.

In vitro susceptibilities of Candida spp. to fluconazole and voriconazole as determined by CLSI disk diffusion testing: ARTEMIS DISK Surveillance Program, 2001 to 2003^a

Species	Susceptibility
	Fluconazoleb			Voriconazoleb
	n	%S	%R	n	%S	%R
C. albicans	49,991	97.8	1.3	47,584	98.6	1.0
C. glabrata	9,040	66.7	16.6	8,719	81.7	10.1
C. tropicalis	5,959	89.1	5.0	5,643	87.1	6.7
C. parapsilosis	5,539	93.2	3.6	5,233	96.8	1.8
C. krusei	2,067	9.4	77.2	1,996	83.2	7.5
C. guilliermondii	662	73.3	9.8	633	91.2	4.9
C. lusitaniae	464	93.3	4.1	445	96.4	2.0
C. rugosa	417	39.3	51.8	394	61.4	26.4
C. kefyr	344	95.3	3.5	331	99.1	0.6
C. famata	253	79.8	11.9	238	89.5	5.5
C. inconspicua	187	25.7	49.2	186	89.2	5.4
C. norvegensis	92	50.0	38.0	91	92.3	1.1
C. dubliniensis	63	96.8	3.2	63	100.0	0.0
C. lipolytica	53	54.7	39.6	52	67.3	19.2
C. pelliculosa	38	94.7	0.0	38	100.00	0.0
C. zeylanoides	37	54.1	37.8	35	74.3	11.4
C. sake	12	83.3	8.3	12	100.0	0.0
Candida spp.c	4,245	86.6	8.2	4,094	92.7	4.7

^aIsolates obtained from 115 institutions in 35 countries.

^bFluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI M44-A. Interpretive breakpoints: S, fluconazole ≥19 mm, voriconazole ≥17 mm: R, fluconazole ≤14 mm, voriconazole ≤13 mm.

^cCandida species not otherwise identified.